Berenberg Initiates Coverage on Gilead Sciences(NASDAQ:GILD). The shares have been rated Buy. The rating by Berenberg was issued on Sep 12, 2016.
In a different note, On Sep 6, 2016, Jefferies said it Upgrades its rating on Gilead Sciences. The shares have been rated ‘Buy’ by the firm. On Aug 31, 2016, Jefferies said it Maintains its rating on Gilead Sciences. In the research note, the firm Lowers the price-target to $93.00 per share. The shares have been rated ‘Hold’ by the firm. On Jul 29, 2016, Argus Research said it Downgrades its rating on Gilead Sciences. The shares have been rated ‘Hold’ by the firm. On Jul 26, 2016, Needham said it Downgrades its rating on Gilead Sciences. The shares have been rated ‘Hold’ by the firm.
Gilead Sciences (GILD) made into the market gainers list on Tuesdays trading session with the shares advancing 3.53% or 2.79 points. Due to strong positive momentum, the stock ended at $81.78, which is also near the day’s high of $82.07. The stock began the session at $79.64 and the volume stood at 1,75,60,698 shares. The 52-week high of the shares is $111.11 and the 52 week low is $76.67. The company has a current market capitalization of $107,922 M and it has 1,31,96,58,490 shares in outstanding.
Gilead Sciences(GILD) last announced its earnings results on Jul 25, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $7.78B. Analysts had an estimated revenue of $7.79B. Earnings per share were $3.08. Analysts had estimated an EPS of $3.00.
Several Insider Transactions has been reported to the SEC. On Sep 8, 2016, John F Milligan (President and CEO) sold 70,000 shares at $77.74 per share price.Also, On Sep 6, 2016, John C Martin (Executive Chairman) sold 100,000 shares at $77.82 per share price.On Aug 25, 2016, Kevin E Lofton (director) sold 3,500 shares at $81.97 per share price, according to the Form-4 filing with the securities and exchange commission.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.